Abstract 2329P
Background
Although it is an important biomarker in oncology, Ki-67 immunohistochemistry analysis has yet to be standardized. Working groups have provided guidelines for Ki-67 scoring in different cancer types to limit pathologist’s variability. Digital analysis solutions to assist scoring with image analysis or AI have recently emerged in the evaluation of Ki-67 as rapid and robust solutions. In this context, we compared the results of Ki-67 scoring performed with Aiforia® (AI platform) and Halo® (image analysis supervised software) against two independent pathologists on solid tumors.
Methods
We stained 192 tumors of various origins including breast and prostate with Ki-67 (clone 30-9). Pathologists were trained following the International Ki-67 Working Group recommendations and scored tissues accordingly. Based on deep learning, Aiforia was able to automatically score Ki-67 positive tumor cells within minutes. The random forest classifier from Halo software was used to separate the image into tumor, non-tumor and background. After cell segmentation, Ki-67 positivity was assessed by thresholding.
Results
Our study shows a very high consistency of results obtained for Ki-67 scoring between the image analysis softwares, Aiforia and Halo (r2=0.94), on all solid tumors. The correlation obtained between the two pathologists was weaker (r2=0.8), despite the training and guidelines, but remains within an acceptable range. Of the 18 types of primary tumors analyzed, only 2 (thyroid and stomach) showed correlations of less than 0.75 between the image analysis softwares with inter-pathologists' correlation still high (0.73 and 0.86). Depending on the organ, there were significant variations between pathologists, whereas the scores obtained with the image analysis softwares remain very close. For example, with prostate (n=8), a 0.81 correlation for Ki-67 scores between Aiforia and Halo was found while the inter-pathologists' correlation was 0.68.
Conclusions
This work shows that AI based image analysis tools such as Aiforia and image analysis supervised software provide valuable assistance in IHC based clinical analysis, drastically reducing inter-pathologist variability or as an arbitration tool in Ki-67 scoring of solid tumors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2357P - TRX-221, a 4th generation, mutant-selective, and CNS-active EGFR inhibitor with robust antitumor activity in osimertinib-resistant tumor models harboring C797S mutation
Presenter: Sumin Lim
Session: Poster session 16
2358P - Assessing the efficacy of robot-assisted total gastrectomy for advanced proximal gastric cancer: Results from a three-year clinical trial
Presenter: Zhi-Yu Liu
Session: Poster session 16